ET140203

N/A

Report date: 2024/12/05 15:26:07

Base Information

Drug NameET140203

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAlpha-fetoprotein modulators

TargetsAlpha-fetoprotein

Therapy Area/IndicationsLiver NeoplasmsCarcinoma, HepatocellularHepatoblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesEureka Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesEureka Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsLiver NeoplasmsCarcinoma, HepatocellularHepatoblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A